GlassScriptPhysician profile
Toug Mark Tanavin
NPI 1760801526
$8,180.87
in general payments reported to CMS, 2019-2025
31 companies · $442 in 2025
The $442 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,295 · 2020: $2,089 · 2021: $676 · 2022: $898 · 2023: $867 · 2024: $915 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,826.52 | 2019-2024 | Gallant, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $699.59 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $609.62 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $362.10 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $360.75 | 2019-2025 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $307.37 | 2020-2025 | |
| Shockwave Medical, INC | $241.12 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.18 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $190.73 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $174.58 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $167.22 | 2022-2025 | Verquvo, Capvaxive |
| Medtronic Vascular, INC. | $139.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $127.93 | 2019-2025 | |
| Philips North America LLC | $103.92 | 2022-2023 | |
| Penumbra, INC. | $96.47 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $92.59 | 2019-2025 | |
| Cardiovascular Systems INC. | $85.73 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.53 | 2021-2024 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $58.22 | 2022-2023 | Arcalyst |
| Amarin Pharma, INC. | $48.30 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $41.66 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $29.92 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $20.66 | 2021 | |
| Astellas Pharma US INC | $20.64 | 2019 | |
| Esperion Therapeutics, INC. | $20.10 | 2023 | Nexletol |
| Azurity Pharmaceuticals, INC. | $18.81 | 2024 | Edarbi |
| Smith+Nephew, INC. | $17.20 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $17.01 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $14.88 | 2020 | |
| Biotronik INC. | $14.83 | 2020 | |
| Medtronic, INC. | $13.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toug Tanavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.